StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$11.14−0.16 (-1.42%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Earnings

NovoCure's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$193.40M
+15.7% on a year earlier
EPS, Q3 FY2026
-$0.09
-$0.33 a year earlier
Latest guidance
Raised
Oct 29, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of NovoCure's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 29, 2026before the open$193.40M+15.7%-$0.09Release
Q2 FY2026ended Jun 30, 2026Jul 23, 2026before the open$183.60M+15.6%-$0.13Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026before the open$174.10M+12.3%-$0.62Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$174.40M+8.1%-$0.22Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025before the open$167.20M+7.8%-$0.33Release
Q2 FY2025ended Jun 30, 2025Jul 24, 2025before the open$158.80M+5.6%-$0.36Release
Q1 FY2025ended Mar 31, 2025Apr 24, 2025before the open$155.00M+11.9%-$0.31Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$161.30M+20.6%-$0.61Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024before the open$155.10M+21.8%-$0.28Release
Q2 FY2024ended Jun 30, 2024Jul 25, 2024before the open$150.40M+19.3%-$0.31Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$138.50M+13.3%-$0.36Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

NovoCure's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total net revenueFY2026$736.00M – $743.00M–NewOct 29, 2026
Total net revenueFY2026$710.00M – $725.00M$690.00M – $710.00MRaisedJul 23, 2026
Total net revenuesGAAPFY2026$675.00M – $705.00M–NewFeb 26, 2026
Adjusted EBITDAnon-GAAPFY2026$24.00M – $34.00M-$20.00M – $0RaisedOct 29, 2026
Adjusted EBITDA*non-GAAPFY2026$0 – $15.00M-$15.00M – $0RaisedJul 23, 2026

Guidance history

Every forecast NovoCure put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 29, 2026Adjusted EBITDAFY2026$24.00M – $34.00MRaised
Oct 29, 2026Total net revenueFY2026$736.00M – $743.00MNew
Jul 23, 2026Adjusted EBITDA*FY2026$0 – $15.00MRaised
Jul 23, 2026Total net revenueFY2026$710.00M – $725.00MRaised
Apr 30, 2026Adjusted EBITDAFY2026-$15.00M – $0New
Apr 30, 2026Total net revenueFY2026$690.00M – $710.00MNew
Feb 26, 2026Adjusted EBITDA*FY2026-$20.00M – $0New
Feb 26, 2026Total net revenuesFY2026$675.00M – $705.00MNew
Apr 28, 2022active patient growthFY2022+2% – +5%Reaffirmed
Feb 24, 2022active patient growthFY2022+2% – +5%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases NovoCure filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Update
  4. Results
  5. Update
  6. Update
  7. Results
  8. Update
  9. Results
  10. Update
  11. Results
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?